Apyx's Surgical Pivot: AYON Platform Fuels Growth and Redefines Strategy

CLEARWATER, FL – August 06, 2026 – Apyx Medical Corporation reported its second-quarter financial results today, revealing a company in the midst of a successful and highly focused transformation. While the headline figure of $13.9 million in total revenue—a 22% year-over-year increase—is impressive, the real story lies deeper within the numbers. The company's Surgical Aesthetics segment surged by a remarkable 28%, pulling in $12.4 million and signaling that Apyx's strategic bet on its proprietary technology is beginning to pay substantial dividends.

This growth isn't a matter of a rising tide lifting all boats; it's the direct result of a calculated pivot toward a higher-margin, integrated technology ecosystem, centered on its AYON Body Contouring System. As the company simultaneously engineers a deliberate retreat from its lower-margin Original Equipment Manufacturer (OEM) business, it is crafting a new narrative focused on innovation, clinical validation, and market leadership in the competitive aesthetics space.

“We are excited by the increasing demand for AYON throughout the U.S. market, which we believe reflects the successful execution of our commercial strategy,” said Charlie Goodwin, President and Chief Executive Officer. “U.S. Surgeons continue to recognize the value of an all-in-one body contouring platform that brings together the technologies they rely on every day.” This sentiment underscores a fundamental shift from selling components to delivering comprehensive solutions.

AYON Ignites a New Growth Phase

The engine driving Apyx's impressive quarter is unquestionably the AYON Body Contouring System. Launched commercially in September 2025, AYON is more than just a new device; it's an integrated platform designed to be the central hub for aesthetic surgeons. The system combines fat removal, closed-loop contouring, and electrosurgical capabilities with Apyx's signature Renuvion technology, which uses helium plasma for controlled tissue heating and contraction.

The strategic value of this all-in-one approach cannot be overstated. By consolidating multiple procedures into a single, streamlined system, Apyx is directly addressing a critical need for efficiency and versatility in the operating room. This quarter's results were further bolstered by a significant milestone: the expanded FDA 510(k) clearance for AYON to include power liposuction. Following a limited launch in June, the company is now preparing for a full commercial rollout of the reusable power liposuction handpiece in the third quarter.

According to industry insiders, the initial feedback from early adopters has been exceptionally positive, with surgeons praising the system’s integrated design. This validation is critical, as the company projects that over 95% of AYON purchasers will adopt the new power liposuction capability, creating a valuable recurring revenue stream from disposable handpieces. More importantly, the AYON platform is proving to be a powerful tool for market expansion, attracting physicians who had not previously used the standalone Renuvion technology. This demonstrates a successful strategy in not just upselling existing customers but capturing entirely new segments of the market.

Redefining Outcomes with Clinical Proof

In the high-stakes world of medical devices, hardware alone is not enough. Sustainable success requires robust clinical data to validate performance and justify investment. Here, Apyx is executing a parallel strategy to fortify its market position. The company recently highlighted two key publications that bolster the clinical case for its core Renuvion technology.

A retrospective clinical study demonstrated that using Renuvion in combination with liposuction was associated with significantly higher patient satisfaction and lower rates of subsequent revision surgeries compared to liposuction alone. For surgeons and patients alike, reducing the need for costly and invasive follow-up procedures is a powerful value proposition. This data provides a compelling clinical argument for integrating Renuvion as a standard of care in body contouring.

Furthermore, another study reported positive data showing significant improvements in both cellulite appearance and skin laxity after a single combination treatment using Renuvion and Avéli. This speaks to the technology's versatility and its potential to address multiple aesthetic concerns simultaneously. It also strategically positions Apyx to capitalize on emerging market trends, such as the growing demand for skin tightening procedures from patients who have undergone significant weight loss, including those using GLP-1 medications.

A Calculated Retreat for a Stronger Core

Perhaps the most telling aspect of Apyx's current strategy is what it's choosing not to do. The company's OEM segment, which provides technology to other medical device manufacturers, saw revenue decrease by 12% to $1.5 million. Far from being a point of concern, this decline is an intended consequence of a deliberate strategic shift. Management has been transparent about its expectation for OEM revenue to decrease for the full year and continue this trend over time.

This move represents a disciplined pivot away from a lower-margin business to concentrate resources on the proprietary, high-growth Surgical Aesthetics segment. The impact of this focus is already visible in the company's financial health. Gross margin expanded to 63.9% in the second quarter, up from 62.3% in the same period last year, with the company attributing the increase primarily to the more favorable revenue mix. By shedding its less profitable operations, Apyx is building a leaner, more resilient business model geared for long-term profitability.

The Financial Blueprint for Growth

This strategic realignment is translating directly to an improved bottom line. The company's net loss attributable to stockholders narrowed to $3.2 million, an improvement from $3.8 million in the prior-year period. More significantly, the Adjusted EBITDA loss shrank dramatically to just $0.7 million, compared to a $2.0 million loss in Q2 2025, demonstrating substantial progress toward operational profitability.

While the path to growth involves investment—cash used in operating activities increased to $3.5 million, largely due to building up inventory for the AYON launch—the company appears well-capitalized to execute its plan. With $27.6 million in cash and cash equivalents, management expressed confidence in its ability to fund operations through 2027. This confidence is supported by the reaffirmation of its full-year 2026 revenue guidance of $59.0 million to $60.0 million, which implies a strong acceleration in the second half of the year.

Wall Street appears to be taking notice of this disciplined transformation. Analysts maintain a consensus "Strong Buy" rating on APYX, with an average price target of $6.60, suggesting significant upside potential. This external validation indicates that investors and analysts alike see the long-term value in Apyx's decision to focus its innovative energy on a core market where it can build a defensible and profitable leadership position.